![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 08, 2019 12:19:48 PM
Very true, sokol.
However, it is not just for this one trial that set-up is crucial/critical for success. It has been the set-up of the entire way the phases are designed to play out that makes this a higher probability of success all around.
Remember the playbook:
It is better to design the overall process to fail quickly, as in the first or second phase, if likely to fail. Dr. Missling has said that you want to do everything correctly in the early phases (if the drug works; implied), to AVOID EVER failing in a phase 3.
Based on how this was designed and thought out from the initial phases (open, no placebo, small, tons of data gathering and dose ranges, and critical analyzing of everything from gut biome to genome sequencing on each patient with greater or less great response), the company has put itself into the position of an “academic” phase 3 in AD, and now with two additional indications following the same drill, all have much greater chance of demonstrating efficacy than of failing.
Dr. Missling has expressed the sentiment that ph 3 is not where drugs should fail. And yet, that’s where they all (most) do or have.
Now, all can discuss that this is why he deserves the options, why we will be a partner target, the timeframe, the SP, the charts...the sea bird, etc.
My proprietary AI software investment analysis program (patent pending) developed at Pittsburgh Supercomputing Center, over 2 years ago using Bridges HPC, designed to analyze all competitors in any sector across specified parameters, now gives AVXL a whopping 89% chance of approval for AD indication. In other word, SUCCESS. That’s compared against a 99.6% historic FAILURE rate in the AD space over the past 30 years. We jumped from 59% to 72% when Biogen caved. (When, not because. Was further evidence of wrong theory - Amyloid.) We jumped to 83% with ph2a extension data. (Because. Was further evidence of our MoA)
Will update if/when numbers change - this was just a sample for today, fwiw.
Contrary to expectations (but not logic), with the announcement of enrollment numbers today...we go to 89%. Slow and steady appears to agree with the historical data significance for success. (Coupled with other parameters)
For those interested: NTRP is running second with a 54% chance of meeting its endpoints. (Disclaimer, this is based on a software program - designed to more accurately choose stocks for whatever purpose to enhance return on investment. I am trialing this now...my future fortune from AVXL gamble is being parlayed.)
Best of luck to all. We will not fail in phase 3. Upon approval, all those who frequent the MB are eligible for a free PC version of the program, in thanks for all the hard work, dedication, thoughts, and levity.
Link to Supercomputer Bridges FYI
https://www.cmu.edu/mcs/news-events/2017/0131-AI-Defeats-Poker-Pros.html
Going forward - we got this,
Bio
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM